ViroPharma Receives Orphan Drug Designation for Camvia

The Committee for Orphan Medicinal Products has granted orphan drug designation to ViroPharma’s Camvia for the prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity.

Camvia (maribavir) is a member of a new class of drugs called benzimidazole ribosides.

ViroPharma began dosing in a Phase III study in solid organ liver transplant patients in September. The company said it hopes to file in U.S. and Europe in 2009.